Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Shares Issued (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Shares Issued for 7 consecutive years, with $234.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued rose 150.81% to $234.8 million in Q4 2025 year-over-year; TTM through Nov 2025 was $234.8 million, a 27.27% increase, with the full-year FY2025 number at $234.8 million, down 18.98% from a year prior.
  • Shares Issued was $234.8 million for Q4 2025 at Nurix Therapeutics, up from -$227000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $234.8 million in Q4 2025 to a low of -$148.5 million in Q4 2021.
  • A 5-year average of $16.2 million and a median of $532000.0 in 2022 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: crashed 450072.73% in 2021, then skyrocketed 173314.29% in 2024.
  • Nurix Therapeutics' Shares Issued stood at -$148.5 million in 2021, then soared by 112.37% to $18.4 million in 2022, then tumbled by 106.76% to -$1.2 million in 2023, then soared by 7642.3% to $93.6 million in 2024, then soared by 150.81% to $234.8 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Shares Issued are $234.8 million (Q4 2025), -$227000.0 (Q3 2025), and -$1.0 million (Q2 2025).